Tricoci Pierluigi, Peterson Eric D
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA.
J Interv Cardiol. 2006 Oct;19(5):449-55. doi: 10.1111/j.1540-8183.2006.00182.x.
Results from clinical trials of glycoprotein IIb/IIIa(GPIIb/IIIa) inhibitors during the past decade have established their current role in the treatment of non-ST-segment elevation acute coronary syndrome and in percutaneous coronary interventions. However, there are still unanswered questions on optimal use of GPIIb/IIIa inhibitors. Moreover, as new concomitant or alternative medications become available, the role of GPIIb/IIIa inhibitors must be reconsidered. This review discusses, in the light of clinical trials recently presented, what we know, what we are learning, and what we still need to learn.
在过去十年中，糖蛋白IIb/IIIa（GPIIb/IIIa）抑制剂的临床试验结果确立了它们目前在治疗非ST段抬高型急性冠状动脉综合征及经皮冠状动脉介入治疗中的作用。然而，关于GPIIb/IIIa抑制剂的最佳使用仍存在未解决的问题。此外，随着新的联合用药或替代药物的出现，必须重新考虑GPIIb/IIIa抑制剂的作用。本综述根据最近公布的临床试验，讨论了我们已知的、正在了解的以及仍需了解的内容。
